Bills › 2025-26
2ESSB 5594: Biosimilar medicines
Data last updated: bill actions through Aug 23, 2026 · lobbyist reports through Sep 30, 2026 (read Oct 14, 2026)
Concerning biosimilar medicines. (REVISED FOR ENGROSSED: Concerning biosimilar medicines and interchangeable biological products.)
- Prime sponsor
- Paul Harris
- Introduced
- Feb 18, 2025
- Status
- By resolution, returned to Senate Rules Committee for third reading. (Mar 12, 2026)
- The Legislature's page
- 2ESSB 5594 on leg.wa.gov
Floor votes
No floor roll call on file (it didn't pass a chamber, or it was decided without one).
Who lobbied on it 10
| Employer | Lobbyists | To 2026 candidates |
|---|---|---|
| Association for Accessible Medicines | 2 | — |
| Association of Washington Healthcare Plans | 2 | — |
| GENENTECH | 2 | $13,000 |
| AARP WA ST OFFICE | 1 | — |
| AMGEN INC | 1 | — |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 1 | — |
| BLEEDING DISORDER FOUNDATION OF WA | 1 | — |
| Elevance Health, and its Affiliates | 1 | $26,400 |
| JOHNSON & JOHNSON SERVICES, INC. | 1 | $3,600 |
| PHARMACEUTICAL RSRCH/MFG OF AMERICA | 1 | — |
Lobbying reports name a bill number, not a position on it or a version of it. Money: what each employer (as a donor to two or more 2026 candidates) gave to the 2026 campaigns of the members who voted yea or nay on the bill's latest final passage in each chamber.